--- title: "NEC Baby Formula Lawsuit: Premature Infant Injury Claims" url: https://www.masstortmarketingagency.com/blogs/nec-baby-formula-lawsuit canonical: https://www.masstortmarketingagency.com/blogs/nec-baby-formula-lawsuit published: 2026-02-12 modified: 2026-02-12 author: name: Tarun role: Founder, Mass Tort Agency publisher: name: Mass Tort Agency url: https://www.masstortmarketingagency.com description: | How cow's milk-based formula is linked to necrotizing enterocolitis (NEC) in premature infants: the science (Lucas & Cole 1990, Sullivan et al. 2010, Cochrane Review), the claims against Abbott (Similac) and Mead Johnson/Reckitt (Enfamil), the status of MDL 3026 in the Northern District of Illinois, plaintiff qualification criteria, and settlement projections for attorneys building an NEC practice. keywords: - NEC baby formula lawsuit - necrotizing enterocolitis - MDL 3026 - Similac Enfamil litigation - premature infant formula claims - NEC qualification criteria license: | Cite freely with attribution to Mass Tort Agency. Verbatim quoting permitted with citation back to the canonical URL. --- # NEC baby formula lawsuit: premature infant injury claims > **Quick answer.** The NEC baby formula lawsuit targets Abbott Laboratories > (Similac) and Mead Johnson/Reckitt Benckiser (Enfamil), alleging their > cow's milk-based formulas caused necrotizing enterocolitis in premature > infants and that the companies failed to warn. Federal cases were > consolidated in April 2022 into MDL 3026 before Judge Rebecca R. Pallmeyer > in the Northern District of Illinois; as of early 2026 the MDL holds well > over a thousand pending cases. Lucas and Cole (The Lancet, 1990) found NEC > six to ten times more common in exclusively formula-fed preterm infants, > and Sullivan et al. (2010) found an exclusive human milk diet reduced > surgical NEC by approximately 77%. Headline figures from the article: **1K+** pending MDL cases, **77%** surgical NEC reduction with exclusive human milk, **6–10x** NEC risk increase with formula, **$671M** DuPont-level precedent. ## Understanding necrotizing enterocolitis and the NEC baby formula lawsuit Necrotizing enterocolitis (NEC) is one of the most devastating gastrointestinal emergencies affecting premature infants, causing inflammation, bacterial invasion, and necrosis of intestinal tissue — often leading to bowel perforation, sepsis, and death. For decades, NICUs have relied on cow's milk-based formulas from Abbott Laboratories (Similac) and Mead Johnson (now owned by Reckitt Benckiser, marketing Enfamil) to feed premature infants. A growing body of evidence shows these products significantly increase NEC risk in preterm neonates compared with exclusive human milk diets. Families of premature infants who developed NEC after being fed Similac or Enfamil products are pursuing claims alleging the manufacturers knew or should have known about the dangers and failed to warn healthcare providers and parents. ## The science: how cow's milk-based formula harms premature infants Premature infants (born before 37 weeks of gestational age) have immature gastrointestinal tracts: underdeveloped intestinal barriers, incomplete mucosal immunity, and unestablished colonization by beneficial gut bacteria. Human breast milk supplies immunoglobulins (notably secretory IgA), lactoferrin, lysozyme, oligosaccharides, and growth factors that protect the immature gut. Cow's milk-based formula deprives preterm infants of these protective factors while exposing them to bovine proteins their systems cannot adequately process. In formula-fed preterm infants, cow's milk proteins trigger an abnormal immune response in the immature intestinal mucosa, increasing permeability; bacteria translocate across the intestinal wall, initiating severe inflammation, tissue ischemia, necrosis, and in severe cases full-thickness bowel perforation. ## Key scientific studies linking formula to NEC - **The Cochrane Systematic Review** (updated multiple times) consistently found formula feeding associated with significantly higher NEC incidence than exclusive human milk feeding in randomized controlled trials. - **Sullivan et al. (Journal of Pediatrics, 2010)** — a prospective multicenter trial in extremely premature infants found an exclusive human milk diet reduced surgical NEC rates by approximately **77%** versus any bovine-based products (including formula and bovine-based human milk fortifiers). - **Lucas and Cole (The Lancet, 1990)** — a prospective multicenter study of 926 preterm infants found NEC **six to ten times more common** in exclusively formula-fed infants than in those fed exclusively breast milk. - Additional studies in Pediatrics, the Journal of Perinatology, Neonatology, and other peer-reviewed journals, plus meta-analyses, have reinforced the association. ## The defendants **Abbott Laboratories (Similac).** Plaintiffs allege Abbott knew the scientific literature linking its cow's milk-based products to NEC yet continued marketing them aggressively to NICUs and hospitals without adequate warnings. Internal documents, scientific advisory board communications, and marketing strategy materials are expected to be central in establishing what Abbott knew and when. **Mead Johnson / Reckitt Benckiser (Enfamil).** Enfamil Premature is one of the most commonly used formulas in U.S. NICUs. Mead Johnson's direct-to-hospital marketing programs, sponsored educational materials, and relationships with neonatologists are under scrutiny; the absence of NEC warnings on its premature infant products despite decades of available evidence forms the core of negligence and strict liability claims. ## MDL 3026: the federal NEC baby formula litigation In April 2022, the Judicial Panel on Multidistrict Litigation consolidated NEC cases into MDL No. 3026, *In Re: Abbott Laboratories, et al., Infant Formula Products Liability Litigation*, assigned to Judge Rebecca R. Pallmeyer in the U.S. District Court for the Northern District of Illinois. As of early 2026, the MDL contains well over a thousand pending cases with new filings continuing monthly. The court has established a bellwether trial selection process, with early rulings on key evidentiary issues favoring the admissibility of expert testimony on the formula–NEC causal link. Importantly, the court rejected manufacturer arguments that federal preemption bars state-law failure-to-warn claims. ## Clinical presentation and Bell staging NEC typically presents within the first two to six weeks of life. Early signs include feeding intolerance, abdominal distension, bloody stools, lethargy, temperature instability, and apneic episodes. The modified Bell staging criteria classify severity: | Stage | Classification | Severity | Treatment | |---|---|---|---| | I | Suspected NEC | Mild systemic signs | Medical management | | II | Definite NEC | Moderate systemic illness | Medical + possible surgical | | III | Advanced NEC | Severe / perforation | Emergency surgery | Survivors often face long-term consequences: surgical NEC requiring bowel resection can cause short bowel syndrome (prolonged parenteral nutrition, potentially intestinal transplantation), plus intestinal strictures, feeding difficulties, growth failure, neurodevelopmental delays, and chronic nutritional deficiencies. Lifetime medical costs can reach millions of dollars. ## Who qualifies: plaintiff screening criteria Core requirements: - **Premature birth:** born before 37 weeks gestational age; very low birth weight (under 1,500 grams) and extremely premature infants (before 32 weeks) are the strongest cases. - **Cow's milk-based formula exposure:** Similac Special Care, Similac NeoSure, Similac Human Milk Fortifier, Enfamil Premature, Enfamil NeuroPro EnfaCare, Enfamil Human Milk Fortifier, or other bovine-based formulas or fortifiers used in the NICU. - **NEC diagnosis:** confirmed diagnosis (Bell Stage II or III strongest; Stage I may qualify). - **Temporal relationship:** NEC diagnosed after introduction of cow's milk-based formula or fortifier. Strongest profiles: infants born before 32 weeks with very low birth weight; NEC progressing to Stage II/III requiring surgery; bowel resection, ostomy, or short bowel syndrome; fatal NEC; well-documented feeding timelines; and primarily or exclusively formula-fed infants. ## Settlement projections and case valuation No global settlement has been reached; analysts project values based on comparable mass torts, injury severity, and the strength of the science: | Case tier | Projected range | Profile | |---|---|---| | Tier 1 (Fatal / most severe) | High six to low seven figures | Death, short bowel syndrome, intestinal transplant | | Tier 2 (Surgical with complications) | Mid-to-high six figures | Bowel resection, lasting health complications | | Tier 3 (Medical management) | Low-to-mid six figures | Confirmed NEC, extended treatment, no surgery | Actual values will depend on bellwether outcomes and settlement negotiations. ## Building a strong NEC case - **Early investigation:** complete NICU records including feeding logs; product identification (brand, product line, lot numbers if available); parent interviews on feeding decisions and warnings received. - **Experts:** neonatologists (standard of care), epidemiologists and biostatisticians (causal evidence), pediatric surgeons (interventions and sequelae), life care planners and economists (future damages). - **Causation:** general causation is well-supported by the literature; specific causation requires analysis of the infant's history, gestational age, feeding timeline, and exclusion of alternative causes. ## NEC litigation timeline - **1990:** Lucas and Cole publish the first major study linking formula to NEC in premature infants. - **2010:** Sullivan et al. show an exclusive human milk diet reduces surgical NEC by 77%. - **2011–2021:** Additional studies reinforce the link; professional organizations update feeding recommendations. - **2021–2022:** First NEC lawsuits filed in federal and state courts. - **April 2022:** JPML consolidates federal cases into MDL 3026 (N.D. Ill.). - **2023–2024:** Discovery, expert disclosures, Daubert motions on general causation. - **2024–2025:** Bellwether selection; case inventory growth. - **2026 and beyond:** Bellwether trials expected; potential settlement negotiations following trial outcomes. ## Related practice areas NEC claims fit naturally alongside other pharmaceutical and product liability mass torts such as [hernia mesh](https://www.masstortmarketingagency.com/mass-tort-leads/hernia-mesh), [hair relaxer cancer](https://www.masstortmarketingagency.com/mass-tort-leads/hair-relaxer), and [Ozempic gastroparesis](https://www.masstortmarketingagency.com/mass-tort-leads/ozempic). NEC lead generation: https://www.masstortmarketingagency.com/mass-tort-leads/nec. ## Frequently asked questions ### What is the NEC baby formula lawsuit about? Claims against Abbott Laboratories (Similac) and Mead Johnson/Reckitt Benckiser (Enfamil) alleging their cow's milk-based formula products caused necrotizing enterocolitis in premature infants, and that the manufacturers knew about the risk and failed to warn healthcare providers and parents. ### Who qualifies for an NEC baby formula lawsuit? Generally, premature infants born before 37 weeks gestational age who were fed cow's milk-based formula (such as Similac or Enfamil products) in the NICU and subsequently developed NEC. Cases involving surgical NEC, death, or severe long-term complications are the strongest claims. ### What is the current status of NEC baby formula litigation? Cases are consolidated in MDL 3026 in the Northern District of Illinois before Judge Rebecca R. Pallmeyer. The litigation is in the bellwether preparation phase, with trial dates being established and the case inventory continuing to grow. ### How much are NEC baby formula cases worth? No global settlement has been reached. Analysts project values from the low six figures for medically managed NEC to potentially seven figures for death or severe permanent injuries such as short bowel syndrome, depending on bellwether outcomes and negotiations. ### What formula products are involved in NEC lawsuits? Similac Special Care, Similac NeoSure, Similac Human Milk Fortifier (Abbott), and Enfamil Premature, Enfamil NeuroPro EnfaCare, and Enfamil Human Milk Fortifier (Mead Johnson/Reckitt Benckiser), plus other cow's milk-based formula and fortifier products used in NICUs. ### What is the statute of limitations for NEC baby formula lawsuits? It varies by state, but because the injured parties are minors, most states toll the limitations period until the child reaches the age of majority (typically 18). In wrongful death cases the statute runs from the date of death under the applicable state statute. Families should consult an attorney promptly to evaluate filing deadlines. ### How can my law firm acquire qualified NEC claimants? Digital campaigns targeting families of premature infants, partnerships with NICU support organizations, referral networks with pediatric healthcare providers, and specialized NEC mass tort lead generation agencies that pre-screen claimants against qualification criteria. ### What evidence do I need to build a strong NEC case? Complete NICU records with feeding logs showing formula type and timing, radiology reports confirming NEC, surgical and pathology reports if applicable, discharge summaries, documentation of ongoing medical needs, and expert testimony from neonatologists and epidemiologists.